Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Christine Whyte

Christine obtained a first class honours degree in Microbiology from the University of Bristol then obtained a DPhil at the University of Oxford, studying gene expression in bacteria. In 1991 she joined Unilever as a management trainee, based in the women’s health and diagnostics company Unipath. She had a number of roles in marketing, research management and clinical trials in the diagnostics company Oxoid (now part of Thermo Fisher Scientific). Christine spent 6 years at Cancer Research Technology where she negotiated a number of licences for clinical stage small molecules and immunotherapeutics, as well as being on the board of the spin-out company Hybrid Biosystems. She also advised several of Cancer Research UK’s drug development committees on matters relating to intellectual property. In 2003 Christine joined Oxxon Therapeutics as In-Licensing Manager before spending some time as a freelance consultant. Christine joined Isis Innovation in October 2007.